Xarelto Litigation: Is It similar To Pradaxa Litigation?
After the latest multi-billion dollar Pradaxa litigation settlement, sufferers who experienced bleeding injuries while using the anticoagulant Xarelto may question whether they have a legitimate claim. There are more than 300 xarelto litigations
being placed in multidistrict lawsuit and much more Xarelto unwanted side effects legal cases being filed, litigants might be pardoned for thinking if xarelto litigation may ultimately match Pradaxa lawsuit. You will find resemblances: both medicines were associated with similar unwanted side effects and face similar failure-to-warn accusations. But while Pradaxa lawsuit was largely moved in 2014, xarelto litigation is now on-going.
Both Xarelto and Pradaxa are the latest generation anticoagulants, promoted to be top-quality options to warfarin. Warfarin (known through the brand of Coumadin) is still available on the market for many years to avoid thrombus and strokes, but requires blood monitoring to make sure patients remain in the therapeutic range. These latest anticoagulants are promoted as not needing blood supervising.
The problem is, however, the lack of a remedy associated with these modern anticoagulants. Anticoagulants prevent bloodstream from clots and great in stopping thrombus and strokes, but harmful for other bleeding issues. Inability of the blood to clot causes it to be harder to prevent bleeding, which means patients taking anticoagulants face a danger of severe bleeding problems. Warfarin comes with an antidote by means of vitamin k supplement. These latest anticoagulants don’t have a broadly recognized antidote, which means once patients using the drugs start bleeding, they can be vulnerable to severe health issues.
Xarelto litigation filed against Bayer and Janssen Pharmaceutical drugs claims the companies fully understood or must have been aware of the chance of serious bleeding occasions, but didn’t correctly alert patients that there is no recognized antidote to Xarelto.
Boehringer Ingelheim, the manufacturer of Pradaxa, encountered around 9,000 legal cases alleging patients were hurt or died consequently of severe bleeding periods from the drug. On May 2014, Boehringer Ingelheim decided to settle nearly 4,000 claims in condition and federal courts for approximately $650 million.
Today another oral blood thinner, Xarelto (rivaroxaban), has also been associated with serious unwanted effects. Numerous legal cases happen to be filed, declaring injuries associated with the pill including critical internal bleeding. While Xarelto isn’t just like Pradaxa, research conducted recently came to the conclusion, patients supplied with both NOACs come with an elevated chance of intestinal bleeding in comparison to patients supplied with warfarin.
Meanwhile, patients and medical researchers should cautiously consider the potential risks and compensation of Xarelto litigation by taking such new anticoagulants.